AbbVie signs up to $757M deal with Beijing's Brise Pharma for two preclinical migraine candidates
read at Endpoints ↗DealNeutral
AbbVie announced a discovery and commercialization agreement with Brise Pharma, a Beijing-based biotech company.
The partnership covers two preclinical migraine programs and is valued at up to $757 million.
The deal, which originated in 2024, aims to advance the candidates toward later-stage development and potential market launch.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “AbbVie, Brise disclose deal for two preclinical migraine meds”
read at Endpoints ↗78 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that